Drug Target Identified for Common Childhood Blood Cancer
LUNAR1-inhibiting drugs hold potential as first alternative to standard chemotherapy
Embargo expired: 31-Jul-2014 12:00 PM EDT
Source Newsroom: NYU Langone Medical Center
Newswise — In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers at NYU Langone Medical Center report that they have identified a possible new drug target for treating the disease.
T-cell acute lymphoblastic leukemia is one of the most common and aggressive childhood blood cancers. An estimated quarter of the 500 adolescents and young adults diagnosed with the cancer each year in the U.S. fail to achieve remission with standard chemotherapy drugs.
In a cover-story report set to appear in the journal Cell online July 31, the NYU Langone team describes how they used advanced genetic scanning techniques to identify 6,023 so-called long, non-coding strands of RNA, vital chemical cousins of DNA, that were active in the immune system T cells taken from 15 boys and girls with T-cell acute lymphoblastic leukemia, but not active in the healthy T cells in three young people without the disease.
Further analysis found that chemically blocking the action of one of those non-protein-producing RNAs, known as leukemia-induced non-coding activator RNA-1, or LUNAR1 for short, stalled leukemia progression.
Study investigators say LUNAR1 was not singled out from RNA typically used by DNA to make proteins, but rather from among the most prevalent RNA — long chemical strands of translated DNA, previously termed “junk DNA” — which can help transcribe DNA but never fully assemble proteins. They say these long non-coding RNAs are increasingly recognized as key to regulating many cell functions.
Senior study investigator and NYU Langone cancer biologist Iannis Aifantis, PhD, says the study offers preliminary evidence that drugs blocking LUNAR1 could treat T-cell acute lymphoblastic leukemia and a long-sought alternative to chemotherapeutic drugs that kill both cancer and normal cells.
Aifantis, a professor and chair of pathology at the Laura and Isaac Perlmutter Cancer Center at NYU Langone, and an early career scientist at the Howard Hughes Medical Institute, also says LUNAR1 could aid in diagnosing the blood cancer.
“Our study shows that LUNAR1 is highly specific for T-cell acute lymphoblastic leukemia and plays a key role in how this cancer develops,” he says, pointing out that overproduction of LUNAR1 was recorded in almost all (90 percent) of leukemia patients tested.
Moreover, Aifantis says, his team’s latest findings suggest that development of future cancer therapies based on the underlying genetics of each patient should involve “not just mutations in someone’s DNA, but also alterations in the makeup of RNA.”
Among the study’s other key findings was that while LUNAR1 does not produce cancerous proteins on its own, its production was essential to the cell-to-cell signaling action of another protein, insulin-like growth factor 1receptor (IGF-1R), already tied to many cancers, including leukemia.
Further laboratory experiments showed that the gene coding for LUNAR1 is near the gene for IGF-1R and located toward the chromosomes’ ends, known as telomeres. When activated, LUNAR1’s position allows it to chemically loop back and, in turn, bind to and activate IGF-1R.
Researchers zeroed in on LUNAR1 by pinpointing those RNAs that also were active in the NOTCH1 biological pathway. They say the NOTCH1 pathway is common to many cancers, but is especially active in at least half of all people with T-cell acute lymphoblastic leukemia. LUNAR1 stood out right away, they say, as the most highly expressed long, non-coding RNA, of which more than half were newly discovered.
According to Aifantis, his team’s research shows that T-cell acute lymphoblastic leukemia, as is the case in many other cancers, could be simply described as a condition of “too much errant signaling.” He says in normal T cells, the long, non-coding RNAs such as LUNAR1 are not transcribed, NOTCH1 is inactive, and there is no looping back of LUNAR1 to activate IGF-1R.
To confirm their findings, researchers also transplanted human leukemia T cells into mice to prompt tumor growth, and chemically blocked LUNAR1 in some of the animals. Tumor growth stalled only in those mice whose LUNAR1 was inactivated.
Aifantis says his team’s next steps are to develop more effective inhibitors of LUNAR1, preferably something that would precisely target any one or more of its 200-plus component nucleotides.
Funding support for the study was provided by the U.S. National Cancer Institute and National Institute of General Medical Sciences, both parts of the National Institutes of Health. Corresponding federal grant numbers are P30 CA016087-30, R01 CA133379, R01 CA149655, R01 CA173636, R01 169784, R01 GM088847, and T32-CA009161-37. Further funding support was provided by the William Lawrence and Blanche Hughes Foundation; the Leukemia and Lymphoma Society (corresponding grant numbers TRP#6340 -11 and LLS#6373-13), the Chemotherapy Foundation, the Irma T. Hirschl Trust, the V Foundation for Cancer Research, and the St. Baldrick’s Foundation.
Besides Aifantis, other NYU Langone researchers involved in these experiments were lead study investigator Thomas Trimarchi, BSc, and study co-investigators Panagiotis Ntziachristos, PhD, and Aristotelis Tsirigos, PhD. Additional research support was provided by Erhan Bilal, PhD, at the IBM Thomas J. Watson Research Center; and Giulia Fabbri, PhD, and Riccardo Dalla-Favera, MD, at Columbia University in New York.
For more information, go to:
About NYU Langone Medical Center:
NYU Langone Medical Center, a world-class, patient-centered, integrated academic medical center, is one of the nation’s premier centers for excellence in clinical care, biomedical research, and medical education. Located in the heart of Manhattan, NYU Langone is composed of four hospitals — Tisch Hospital, its flagship acute care facility; Rusk Rehabilitation; the Hospital for Joint Diseases, the Medical Center’s dedicated inpatient orthopaedic hospital; and Hassenfeld Children’s Hospital, a comprehensive pediatric hospital supporting a full array of children’s health services across the Medical Center — plus the NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. The Medical Center’s tri-fold mission to serve, teach, and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education, and research. For more information, go to www.NYULMC.org, and interact with us on Facebook, Twitter, and YouTube.